middle.news
Neurotech’s NTI164 Clears Key Safety Hurdle in 28-Day Toxicology Trials
3:19am on Monday 2nd of June, 2025 AEST
•
Healthcare
Read Story
Neurotech’s NTI164 Clears Key Safety Hurdle in 28-Day Toxicology Trials
3:19am on Monday 2nd of June, 2025 AEST
Key Points
NTI164 showed no adverse effects in 28-day repeat-dose studies in rats and dogs
Studies conducted under GLP and ICH guidelines to support FDA, TGA, and EMA filings
No systemic or organ-specific toxicities observed, with all incidental findings resolving post-recovery
Results underpin progression to longer-term toxicology studies and clinical trials
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
NEUROTECH INTERNATIONAL (ASX:NTI)
OPEN ARTICLE